Figure 2.
Virologic outcomes on the day of TLD transition, and 24 and 48 weeks after transition to TLD, with viral suppression defined as <200 copies/mL. Abbreviation: TLD, tenofovir/lamivudine/dolutegravir.

Virologic outcomes on the day of TLD transition, and 24 and 48 weeks after transition to TLD, with viral suppression defined as <200 copies/mL. Abbreviation: TLD, tenofovir/lamivudine/dolutegravir.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close